Exploration results of dataset GSE33658, which based on a phase II neoadjuvant trial of anastrozole (A), fulvestrant (F), and gefitinib (G) in patients with ER+ breast cancer, showed that decreased expression of LEM4 was associated with complete response or partial response to both AF-treatment and AFG-treatment. Here, ESR1 is linked to atrial fibrillation.